{"filing":{"accession_number":"0001628280-26-051964","cik":"0000834365","ticker":"BLFS","company_name":"BIOLIFE SOLUTIONS INC","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"blfs-20260803.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/834365/000162828026051964/blfs-20260803.htm"},"events":[{"id":23248,"run_id":21018,"accession_number":"0001628280-26-051964","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"The filing discloses a previously announced merger agreement between BioLife Solutions and Repligen Corporation, with a two-step merger structure (First Merger and Second Merger) resulting in BioLife becoming a wholly owned subsidiary of Repligen. The Item 7.01 disclosure provides supplemental information regarding the transaction through an employee video and email from management, confirming the transaction remains pending regulatory and shareholder approvals with expected close in Q4 2026. This is a material acquisition/change of control event.","company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23434,"accession_number":"0001628280-26-051964","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a previously announced merger agreement between BioLife Solutions and Repligen Corporation, with a two-step merger structure (First Merger and Second Merger) resulting in BioLife becoming a wholly owned subsidiary of Repligen. The Item 7.01 disclosure provides supplemental information regarding the transaction through an employee video and email from management, confirming the transaction remains pending regulatory and shareholder approvals with expected close in Q4 2026. This is a material acquisition/change of control event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:52:18.890832+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23434,"accession_number":"0001628280-26-051964","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a previously announced merger agreement between BioLife Solutions and Repligen Corporation, with a two-step merger structure (First Merger and Second Merger) resulting in BioLife becoming a wholly owned subsidiary of Repligen. The Item 7.01 disclosure provides supplemental information regarding the transaction through an employee video and email from management, confirming the transaction remains pending regulatory and shareholder approvals with expected close in Q4 2026. This is a material acquisition/change of control event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:52:18.890832+00:00","company_name":"BIOLIFE SOLUTIONS INC","ticker":"BLFS","filing_date":"2026-08-03"}]}